CX3CL1 — Fractalkine (C-X3-C Motif Chemokine Ligand 1)
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">CX3CL1 — C-X3-C Motif Chemokine Ligand 1 (Fractalkine)</th>
</tr>
<tr> [@hundhausen2003]
<td class="label">Symbol</td> [@limatola2014]
<td><strong>CX3CL1</strong></td> [@lee2010]
</tr> [@bhaskar2010]
<tr> [@morganti2012]
<td class="label">Full Name</td> [@cardona2006a]
<td>C-X3-C Motif Chemokine Ligand 1 (Fractalkine / Neurotactin)</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>16q13</td>
</tr>
<tr>
<td class="label">NCBI Gene</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/6376" target="_blank">6376</a></td>
</tr>
<tr>
<td class="label">Ensembl</td>
<td><a href="https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000006210" target="_blank">ENSG00000006210</a></td>
</tr>
<tr>
<td class="label">OMIM</td>
<td><a href="https://omim.org/entry/601880" target="_blank">601880</a></td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/P78423" target="_blank">P78423</a></td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>[Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), [ALS](/diseases/amyotrophic-lateral-sclerosis), [Multiple Sclerosis](/diseases/multiple-sclerosis)</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>[Neurons](/entities/neurons) ([cortex](/brain-regions/cortex), hippocampus), Endothelial cells, Dendritic cells</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">ALZHEIMER</a>, <a href="/wiki/alzheimer's" style="color:#ef9a9a">ALZHEIMER'S</a>, <a href="/wiki/alzheimer's-disease" style="color:#ef9a9a">ALZHEIMER'S DISEASE</a>, <a href="/wiki/amyotrophic-lateral-sclerosis" style="color:#ef9a9a">AMYOTROPHIC LATERAL SCLEROSIS</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">237 edges</a></td>
</tr>
</table>
CX3CL1 — Fractalkine
Pathway Diagram
Mermaid diagram (expand to render)
Overview
CX3CL1 (C-X3-C Motif Chemokine Ligand 1), also known as fractalkine or neurotactin, encodes the sole member of the CX3C chemokine family. Located on chromosome 16q13, the gene produces a unique transmembrane chemokine that exists in both membrane-anchored and soluble forms, each with distinct signaling functions in the central nervous system[@harrison2012].
CX3CL1 is constitutively expressed at high levels by [neurons](/cell-types/neurons) throughout the brain, particularly in the cerebral cortex, [hippocampus](/brain-regions/hippocampus), [striatum](/brain-regions/striatum), and [thalamus](/brain-regions/thalamus). Its receptor, [CX3CR1](/genes/cx3cr1), is predominantly expressed on [microglia](/cell-types/microglia-neuroinflammation), establishing the CX3CL1–CX3CR1 axis as a primary mechanism of neuron–microglia communication[@paolicelli2014].
Dysregulation of CX3CL1 signaling has been implicated in [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), [amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis), and other neurodegenerative conditions where aberrant microglial activation contributes to disease progression.
Gene Structure and Protein Products
Genomic Organization
The CX3CL1 gene spans approximately 15.5 kb on chromosome 16q13 and contains three exons. The promoter region contains binding sites for [NF-κB](/entities/nf-kb), AP-1, and CREB transcription factors, enabling activity-dependent and inflammation-responsive regulation of expression[@bhatt2018].
Protein Structure
The CX3CL1 protein (373 amino acids) has a distinctive domain architecture:
- Chemokine domain (N-terminal): Contains the CX3C motif with three amino acids between the first two cysteines, enabling receptor binding and chemoattraction
- Mucin-like stalk: A heavily glycosylated extended structure (~241 amino acids) that projects the chemokine domain away from the cell surface
- Transmembrane domain: Anchors the protein in the plasma membrane
- Cytoplasmic tail: Short intracellular domain involved in signaling and recycling
A critical feature of CX3CL1 biology is its dual existence:
Membrane-anchored CX3CL1: Functions as an adhesion molecule, mediating direct cell-cell contact between neurons and microglia. Promotes microglial quiescence and neuroprotection through tonic [CX3CR1](/genes/cx3cr1) signaling[@cardona2006].
Soluble CX3CL1 (sCX3CL1): Generated by proteolytic cleavage of the membrane form by [ADAM10](/genes/adam10) (constitutive) and [ADAM17](/genes/adam17)/TACE (inducible). Soluble fractalkine acts as a chemoattractant, recruiting microglia and monocytes to sites of neuronal injury[@hundhausen2003].
Function
Neuron–Microglia Communication
CX3CL1 serves as the primary "off" signal from neurons to microglia, maintaining microglial homeostasis in the healthy brain:
- Microglial quiescence: Tonic CX3CL1–CX3CR1 signaling keeps microglia in a ramified, surveillance state with anti-inflammatory gene expression
- Synaptic maintenance: CX3CL1 signaling regulates [microglial synaptic pruning](/mechanisms/microglial-synaptic-pruning-dysregulation), ensuring appropriate elimination of weak synapses during development and homeostatic plasticity[@paolicelli2014]
- Phagocytic regulation: Modulates [microglial phagocytosis](/mechanisms/microglial-phagocytosis) of cellular debris, dead neurons, and protein aggregates
- Inflammatory gating: Loss of CX3CL1 signaling disinhibits microglia, leading to excessive pro-inflammatory cytokine release including IL-1β, TNF-α, and IL-6
Neuroprotective Functions
CX3CL1 exerts direct and indirect neuroprotective effects:
- Promotes neuronal survival through ERK1/2 and PI3K/[AKT](/genes/akt1) signaling in neurons
- Enhances [BDNF](/genes/bdnf) release from microglia, supporting synaptic plasticity
- Regulates glutamate receptor trafficking at synapses, preventing excitotoxicity
- Modulates [neuroinflammation](/mechanisms/neuroinflammation) by restraining over-activated microglial responses[@limatola2014]
Chemotaxis and Immune Cell Recruitment
Soluble CX3CL1 functions as a potent chemoattractant:
- Recruits CX3CR1+ microglia to sites of neuronal damage
- Attracts peripheral monocytes across the [blood-brain barrier](/entities/blood-brain-barrier) during [neuroinflammation](/mechanisms/neuroinflammation)
- Mediates NK cell and T cell recruitment in neuroinflammatory conditions
Disease Associations
Alzheimer's Disease
CX3CL1 plays a complex, context-dependent role in [Alzheimer's disease](/diseases/alzheimers-disease):
- Amyloid pathology: CX3CR1 knockout in [APP](/entities/app-protein) transgenic mice reduces [amyloid-beta](/proteins/amyloid-beta) deposition by enhancing microglial phagocytic activity, suggesting CX3CL1 normally restrains amyloid clearance[@lee2010]
- [Tau](/proteins/tau) pathology: Conversely, CX3CR1 deficiency in tau transgenic mice exacerbates [tau hyperphosphorylation](/mechanisms/tau-hyperphosphorylation) and neurodegeneration, indicating CX3CL1 signaling protects against tau-mediated toxicity[@bhaskar2010]
- Biomarker potential: CSF soluble CX3CL1 levels are elevated in early AD and correlate with tau but not amyloid-beta levels, suggesting utility as a neuroinflammation biomarker
- Genetic variants: The CX3CR1 V249I/T280M haplotype affects receptor function and has been associated with modified AD risk in some populations
Parkinson's Disease
In [Parkinson's disease](/diseases/parkinsons-disease), CX3CL1 modulates [dopaminergic neuron](/cell-types/dopaminergic-neurons) vulnerability:
- Loss of CX3CL1 signaling enhances [MPTP](/therapeutics/mptp-model)-induced dopaminergic neuron death through excessive microglial activation
- CX3CL1 overexpression in [substantia nigra](/brain-regions/substantia-nigra) protects dopaminergic neurons in toxin models
- Soluble CX3CL1 injection into the striatum reduces neuroinflammation and neuronal loss in 6-OHDA models[@morganti2012]
- [Alpha-synuclein](/proteins/alpha-synuclein) aggregates downregulate neuronal CX3CL1 expression, creating a feed-forward loop of microglial activation
Amyotrophic Lateral Sclerosis
In [ALS](/diseases/amyotrophic-lateral-sclerosis):
- CX3CL1 levels decline in the spinal cord during disease progression in [SOD1](/entities/sod1) mutant mice
- CX3CR1 deficiency accelerates motor neuron loss and disease onset in SOD1-G93A mice
- Fractalkine signaling modulates the transition from neuroprotective to neurotoxic microglial phenotypes[@cardona2006a]
Multiple Sclerosis
- CX3CL1 is expressed on endothelial cells at the blood-brain barrier and regulates immune cell transmigration
- Elevated CSF CX3CL1 correlates with disease activity and relapse in relapsing-remitting MS
Expression
Brain Distribution
CX3CL1 shows a distinctive pattern of neuronal expression in the brain:
- Cerebral cortex: Layers II/III and V pyramidal neurons show high expression
- Hippocampus: Abundant in CA1-CA3 pyramidal neurons and dentate gyrus granule cells
- Striatum: Medium spiny neurons express CX3CL1
- Thalamus: Multiple thalamic nuclei show moderate expression
- Substantia nigra: Dopaminergic neurons express CX3CL1
- Spinal cord: Motor neurons express CX3CL1 constitutively
Expression data from the [Allen Brain Atlas](https://portal.brain-map.org/) confirms widespread neuronal expression with regional variation correlating with vulnerability to neurodegeneration.
Regulation of Expression
CX3CL1 expression is regulated by:
- Neuronal activity: Glutamate receptor activation upregulates CX3CL1 via CREB-dependent transcription
- Inflammation: TNF-α and IL-1β increase CX3CL1 expression via NF-κB, potentially as a compensatory anti-inflammatory response
- Hypoxia: HIF-1α activation induces CX3CL1 in neurons and endothelial cells
- Aging: CX3CL1 expression declines with age, particularly in the hippocampus, potentially contributing to age-related neuroinflammation
Therapeutic Implications
CX3CL1 as Therapeutic Target
The CX3CL1–CX3CR1 axis presents opportunities for therapeutic intervention:
Recombinant fractalkine: Administration of soluble CX3CL1 protects neurons in preclinical models of AD, PD, and stroke
Gene therapy: AAV-mediated CX3CL1 overexpression in the CNS reduces neuroinflammation in mouse models
Small molecule CX3CR1 modulators: Being developed for precise modulation of microglial activation state
Biomarker development: CSF and plasma sCX3CL1 as markers of microglial activation and neuron-microglia interaction statusChallenges
- The dual role of CX3CL1 in amyloid (promoting) vs. tau (protective) pathology complicates therapeutic strategies in AD
- Systemic CX3CR1 blockade could affect peripheral immune surveillance
- Timing of intervention is critical: CX3CL1 augmentation may be beneficial early but less effective in late-stage disease
Key Publications
[Harrison et al., Role for fractalkine/CX3CL1 in the biology of neurodegenerative diseases (2012)](https://pubmed.ncbi.nlm.nih.gov/22500670/)
[Paolicelli et al., Fractalkine regulation of microglial physiology and consequences on the brain and behavior (2014)](https://pubmed.ncbi.nlm.nih.gov/24434769/)
[Limatola & Bhatt, Chemokine CX3CL1 protects neuron–glia communication (2014)](https://pubmed.ncbi.nlm.nih.gov/24462664/)
See Also
- [CX3CR1](/genes/cx3cr1) — Fractalkine receptor (CX3C chemokine receptor 1)
- [Microglia–Neuroinflammation](/mechanisms/microglia-neuroinflammation) — Microglial activation in neurodegeneration
- [TREM2](/genes/trem2) — Triggering receptor expressed on myeloid cells 2
- [Disease-Associated Microglia](/mechanisms/disease-associated-microglia) — DAM phenotype in neurodegeneration
- [Microglial Phagocytosis](/mechanisms/microglial-phagocytosis) — Phagocytic clearance mechanisms
- [Neuroinflammation](/mechanisms/neuroinflammation) — Central nervous system inflammatory mechanisms
External Links
- [NCBI Gene: CX3CL1](https://www.ncbi.nlm.nih.gov/gene/6376)
- [UniProt: P78423](https://www.uniprot.org/uniprot/P78423)
- [OMIM: 601880](https://omim.org/entry/601880)
- [GeneCards: CX3CL1](https://www.genecards.org/cgi-bin/carddisp.pl?gene=CX3CL1)
- [Allen Brain Atlas: CX3CL1](https://portal.brain-map.org/)
References
[Harrison et al., Role for fractalkine/CX3CL1 in the biology of neurodegenerative diseases (2012) (2012)](https://pubmed.ncbi.nlm.nih.gov/22500670/)
[Paolicelli et al., Fractalkine regulation of microglial physiology and consequences on the brain and behavior (2014) (2014)](https://pubmed.ncbi.nlm.nih.gov/24434769/)
[Bhatt et al., Transcriptional regulation of CX3CL1 gene promoter (2018) (2018)](https://pubmed.ncbi.nlm.nih.gov/29427570/)
[Cardona et al., Control of microglial neurotoxicity by the fractalkine receptor (2006) (2006)](https://pubmed.ncbi.nlm.nih.gov/16998468/)
[Hundhausen et al., The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (2003) (2003)](https://pubmed.ncbi.nlm.nih.gov/12697768/)
[Unknown, Limatola & Bhatt, Chemokine CX3CL1 protects neuron–glia communication in the nervous system (2014) (2014)](https://pubmed.ncbi.nlm.nih.gov/24462664/)
[Lee et al., CX3CR1 deficiency alters microglial activation and reduces beta-amyloid deposition in two Alzheimer's disease mouse models (2010) (2010)](https://pubmed.ncbi.nlm.nih.gov/20660255/)
[Bhaskar et al., Regulation of tau pathology by the microglial fractalkine receptor (2010) (2010)](https://pubmed.ncbi.nlm.nih.gov/20838685/)
[Morganti et al., The soluble isoform of CX3CL1 is necessary for neuroprotection in a mouse model of Parkinson's disease (2012) (2012)](https://pubmed.ncbi.nlm.nih.gov/22508956/)
[Cardona et al., Control of microglial neurotoxicity by the fractalkine receptor (2006) (2006)](https://pubmed.ncbi.nlm.nih.gov/16998468/)Pathway Diagram
The following diagram shows the key molecular relationships involving CX3CL1 — Fractalkine (C-X3-C Motif Chemokine Ligand 1) discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)